ArriVent BioPharma 3Q 2026: Revenue $5M, EPS ($0.81) — 10-Q Summary

ArriVent BioPharma reported $5M in collaboration revenue for 3Q 2026, up from none a year earlier, driven by an ARR-002 license agreement. Net loss widened to $40.31M, or $0.81 per share, due to higher R&D and administrative costs. The company's Phase 3 trial for firmonertinib did not meet its primary endpoint.

Original reporting

tradingview.com

Published Nov 9, 2026, 9:31 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 9:40 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

ArriVent BioPharma 3Q 2026: Revenue $5M, EPS ($0.81) — 10-Q Summary — source image — Source · tradingview.com

Decision brief

The 30-second read

$AVBPBearishMed

Why it matters

The 10‑Q reveals a revenue boost from the license upfront payment but a deeper net loss, highlighting cash burn concerns while also showing progress in its pipeline.

Market read

The filing provides fresh quarterly financials for a micro‑cap biotech, offering traders new data to reassess valuation and risk.

What to watch

Potential upside from the Phase 1 ARR‑002 trial and the exclusive China license, which may not be fully priced in yet.

Relevance 7/10Novelty 8/10Timing: post‑market

Background

ArriVent BioPharma is a clinical‑stage biotech focused on oncology, recently securing an exclusive license for its ARR‑002 program in Greater China.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AVBPBearishHigh confidence

Context

ArriVent BioPharma filed its 10‑Q reporting $5 M collaboration revenue and a widened net loss of $40.31 M for Q3 2026.

Expected impact

likely downside as investors price in the widened loss despite the new revenue stream.

Evidence & confidence

First‑time disclosure of quarterly results; loss expansion is a material negative for a micro‑cap biotech.

Market effects

Sector

Biotech sector may see modest caution as early‑stage trial failures and loss expansion are highlighted.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low global relevance; impact confined to niche biotech investors.

Counterpoint

What could challenge this read

The $5 M upfront license payment could signal future cash flow upside if the partnership in Greater China expands.

Key entities

partner
Allist
Company granting exclusive Greater China license for ARR‑002.

Read at source ← All news

$AVBPHighAI 8/10

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

rttnews.comNov 10

$AVBPMed

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

SEC EDGAR 8-KNov 9

$AVBPMedAI 8/10

Truist raises ArriVent BioPharma stock price target on drug data

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

investing.comOct 27

$AVBPMed

Guggenheim maintains Buy rating on ArriVent BioPharma, $30 price target

Guggenheim kept a Buy rating on ArriVent BioPharma (AVBP) with a $30 price target, suggesting a 95.3% upside from the Oct 26 close. The firm cited promising early Phase 1 data for ARR-217 in metastatic colorectal cancer, raising its probability of success to 45%. Recent analyst price targets for AVBP range from $18 to $29.

tradingview.comOct 27

$AVBPMedAI 9/10

ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.

finance.yahoo.comOct 27

$AVBPHighAI 9/10

ArriVent BioPharma Reports 44.8% Response Rate for ARR-217 in Phase 1 CRC Data

ArriVent BioPharma reported Phase 1 data for ARR-217, showing a 44.8% response rate at 6 mg/kg in pretreated colorectal cancer patients. The disease control rate was 93.1% at this dose. At 4 mg/kg and higher, the response rate was 34.2% with a 91.8% disease control rate. Grade 3 or higher adverse events occurred in 30.1% of patients. The company plans to advance to Phase 1b dose optimization.

tradingview.comOct 26